Nabriva Therapeutics (Nabriva Therapeutics) Buyback Yield % : 0.00 (As of May. 02, 2024)

View and export this data going back to 2017. Start your Free Trial

What is Nabriva Therapeutics Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Nabriva Therapeutics's current buyback yield was 0.00%.

Nabriva Therapeutics Buyback Yield % Historical Data

The historical data trend for Nabriva Therapeutics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nabriva Therapeutics Buyback Yield % Chart

Nabriva Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Buyback Yield %

Get a 7-Day Free Trial

-51.10

-16.14

-104.80

-82.17

-35.09

Nabriva Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Buyback Yield %	Get a 7-Day Free Trial															-13.71	-4.90	-	-	-

Competitive Comparison of Nabriva Therapeutics's Buyback Yield %

For the Biotechnology subindustry, Nabriva Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nabriva Therapeutics's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nabriva Therapeutics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Nabriva Therapeutics's Buyback Yield % falls into.

Nabriva Therapeutics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Nabriva Therapeutics's Buyback Yield for the fiscal year that ended in Dec. 2022 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (0	+	2.123)	/	6.0506838
	=	-35.09%

Nabriva Therapeutics's annualized Buyback Yield for the quarter that ended in Jun. 2023 is calculated as

Buyback Yield	=	Net Issuance of Stock		(Annualized)			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	*	Annualized Factor	/	Market Cap
	=	- (0	+	0)	*	4	/	4.8785684
	=	0.00%

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Jun. 2023) data.

Nabriva Therapeutics Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Nabriva Therapeutics's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Nabriva Therapeutics (Nabriva Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nabriva Therapeutics PLC (OTCPK:NBRVF) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Alexandra House, Office 225/227, The Sweepstakes, Dublin, IRL, 4

Website

https://www.nabriva.com

Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.

Executives

Hogan H Michael Iii	officer: Chief Executive Officer	C/O 3D SYSTEMS, 26081 AVENUE HALL, VALENCIA CA 91355
David Maggio	officer: Chief Financial Officer	15950 N. DALLAS PARKWAY, SUITE 600, DALLAS TX 75248
Mark Corrigan	director
Broom Colin Md	officer: Chief Executive Officer	119 FRINGETREE DRIVE, WEST CHESTER PA 19380
Stephen W Webster	director	C/O OPTIMER PHARMACEUTICALS, INC, 101 HUDSON STREET, SAN DIEGO CA 07302
Daniel D Burgess	director	C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121
Carrie L. Bourdow	officer: Director	C/O TREVENA, INC., 1018 WEST 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Rowland Charles A Jr	director	3338 LANCASHIRE RD, FURLONG PA 18925
Theodore R Schroeder	officer: Chief Executive Officer	12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
J. Christopher Naftzger	officer: General Counsel and Corp Sec	633 LOWTHER ROAD, LEWISBERRY PA 17339
Christine J. Guico-pabia	officer: Chief Medical Officer	C/O NABRIVA THERAPEUTICS PLC, 414 COMMERCE DRIVE, SUITE 120, FORT WASHINGTON PA 19034
Lisa Dalton	director	3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
Daniel Dolan	officer: Chief Financial Officer	C/O NABRIVA THERAPEUTICS PLC, 1000 CONTINENTAL DRIVE, SUITE 600, KING OF PRUSSIA PA 19406
Francesco Maria Lavino	officer: Chief Commercial Officer	1000 CONTINENTAL DRIVE, SUITE 600, KING OF PRUSSIA PA 19406
Robert Crotty	officer: General Counsel & Corp Sec.	1301 2ND AVE, SEATTLE WA 98101